TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12585724

Group type: EXPERIMENTAL
Intervention: L-carnosine (800 mg daily for 8 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 10214738

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 11
Study: 7737260

Group type: EXPERIMENTAL
Intervention: Bethanechol (12.5, 25, and 50 micrograms kg‐1 h‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Atropine (5 micrograms kg‐1 h‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Loxiglumide (10 mg kg‐1 h‐1)
Number of subjects: 8
Study: 2048810

Group type: EXPERIMENTAL
Intervention: APRV
Number of subjects: 9

Group type: COMPARATOR
Intervention: SIMV
Number of subjects: 9
Study: 7093133

Group type: EXPERIMENTAL
Intervention: BCG (Tice strain)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study: 31306076

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo treatment (sham appliance)
Number of subjects: 38
Study: 30552531

Group type: EXPERIMENTAL
Intervention: Mastery Enhancement Therapy
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control
Number of subjects: 134
Study: 30378151

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (GTN)
Number of subjects: 43

Group type: COMPARATOR
Intervention: L-NMMA (n=13)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Ketorolac (n=14)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Fluconazole (n=16)
Number of subjects: 43
Study: 28767584

Group type: EXPERIMENTAL
Intervention: Rational-emotive health education intervention (REHEI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 25932544

Group type: EXPERIMENTAL
Intervention: Lacosamide 400 mg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lacosamide 800 mg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg/day
Number of subjects: 100
Study: 23153560

Group type: EXPERIMENTAL
Intervention: Rifampicin (300mg/d) alone for 7 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rifampicin (300mg/d) with SFN (450μmol)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SFN (450μmol) alone
Number of subjects: 24
Study: 21598023

Group type: EXPERIMENTAL
Intervention: Home-based behavioral interventions
Number of subjects: 452
Study: 19506391

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (1.3, 2.0, and 2.7 mg/m²/day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 39
Study: 16522903

Group type: EXPERIMENTAL
Intervention: Mediterranean-inspired diet (MID)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ordinary Swedish diet (OSD)
Number of subjects: 22
Study: 15449633

Group type: EXPERIMENTAL
Intervention: Heat wrap therapy
Number of subjects: 371

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 371

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 371
Study: 11269569

Group type: EXPERIMENTAL
Intervention: Fasting for 10 hours
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ingestion 1 hour before breakfast
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ingestion immediately following consumption of the breakfast
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ingestion 1.5 hours after beginning consumption of the breakfast
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ingestion immediately after meal vs 1.5 hours postmeal
Number of subjects: 16
Study: 9408426

Group type: EXPERIMENTAL
Intervention: Heparin-coated 7-FR femoral venous catheters
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control legs (contralateral leg without catheter)
Number of subjects: 42
Study: 8208641

Group type: EXPERIMENTAL
Intervention: Lisinopril 10‐40 mg once daily
Number of subjects: 127

Group type: COMPARATOR
Intervention: Nifedipine 20‐40 mg twice daily
Number of subjects: 127
Study: 3114434

Group type: EXPERIMENTAL
Intervention: CHAP-5 (doxorubicin and a five‐day course of cisplatin alternating with cyclophosphamide and hexamethylmelamine orally for 14 days)
Number of subjects: 191

Group type: COMPARATOR
Intervention: CP (cyclophosphamide and cisplatin both administered intravenously on a single day at 3‐week intervals)
Number of subjects: 191
Study: 29121334

Group type: EXPERIMENTAL
Intervention: 2.5 mg dronabinol
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 10 mg dronabinol
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 27005755

Group type: EXPERIMENTAL
Intervention: Simulation training for EVAR
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Infrarenal device
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Suprarenal device
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Suprarenal fixation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Femoral access side
Number of subjects: 18
Study: 24934484

Group type: EXPERIMENTAL
Intervention: Cilostazol (up to 200 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 24131885

Group type: EXPERIMENTAL
Intervention: Exercise session (EX)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control session (CON)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bed rest session (BR)
Number of subjects: 10
Study: 20578138

Group type: EXPERIMENTAL
Intervention: Band ligation plus nadolol (Combined group)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Nadolol alone (Nadolol group)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study: 19105351

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine treatment for flat warts, 5 g pre-pack, treated for 30 days.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Western medicine treatment for flat warts (control group).
Number of subjects: 0
Study: 16632814

Group type: EXPERIMENTAL
Intervention: tropisetron (0.1 mg/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: clonidine (1.5 microg/kg)
Number of subjects: 75
Study: 12741308

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pumping (IABP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no IABP)
Number of subjects: 21
Study: 10843152

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg
Number of subjects: 299

Group type: COMPARATOR
Intervention: Calcitonin 200 IU
Number of subjects: 299
Study: 8983912

Group type: EXPERIMENTAL
Intervention: Ebastine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carebastine
Number of subjects: 0
Study: 2205961

Group type: EXPERIMENTAL
Intervention: 100 mg zinc sulphate as a depot tablet = 22 mg Zn++ (Zinclet), taken thrice daily for eight weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo, taken thrice daily for eight weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 100 mg zinc sulphate as a depot tablet = 22 mg Zn++ (Zinclet)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 626821

Group type: EXPERIMENTAL
Intervention: Combination of hepatic artery ligation and portal vein perfusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hepatic artery ligation and perfusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Portal vein perfusion alone
Number of subjects: 0
Study: 31831201

Group type: EXPERIMENTAL
Intervention: ESM-derived personalised feedback
Number of subjects: 50

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 50
Study: 31399448

Group type: EXPERIMENTAL
Intervention: Glutathione (GSH) infusion (2500 mg/25 mL over 10 min, followed by the same doses at 24, 48, and 72 hours)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 28122364

Group type: EXPERIMENTAL
Intervention: Sucrose (S)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sucrose + Maltodextrin (S+M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deionized Distilled Water (DDW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maltodextrin (M)
Number of subjects: 0
Study: 25348807

Group type: EXPERIMENTAL
Intervention: Subcutaneous infiltration of both wound edges with 20 ml of 0.75% ropivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isotonic saline infiltration (placebo)
Number of subjects: 40
Study: 23480028

Group type: EXPERIMENTAL
Intervention: Fentanyl (5 μg/kg) intravenously alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fentanyl (5 μg/kg) intravenously with rifampicin (600 mg single oral dose)
Number of subjects: 16
Study: 22153009

Group type: EXPERIMENTAL
Intervention: tirofiban + aspirin and clopidogrel
Number of subjects: 325
Study: 19786678

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (ACEIs)
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Dihydropyridine calcium channel blocker (CCB)
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Beta-blocker (BB)
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: Diuretic use
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: GFR between 31 and 40 mL/min/1.73 m²
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: GFR < 30 mL/min/1.73 m²
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: GFR 41 to 50 mL/min/1.73 m²
Number of subjects: 1094
Study: 16941613

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium nasal spray
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium nasal spray and hydroxyurea capsule
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 17

Group type: COMPARATOR
Intervention: Hydroxyurea capsule and placebo nasal spray
Number of subjects: 17
Study: 16510377

Group type: EXPERIMENTAL
Intervention: Fluvastatin XL 80 mg once daily
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 130
Study: 14753137

Group type: EXPERIMENTAL
Intervention: General anesthesia with propofol and remifentanil (2 and 0.2‐0.4 microgram/Kg/h)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Subarachnoid anesthesia with lidocaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Subarachnoid anesthesia with 1.5% prilocaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 120
Study: 9476719

Group type: EXPERIMENTAL
Intervention: MRI‐based linear measurements of the hippocampus and parahippocampal gyrus complex
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Left height of the HPC at the level of the mammillary bodies
Number of subjects: 87
Study: 7709462

Group type: EXPERIMENTAL
Intervention: Lisinopril (LIS, 10‐20 mg o.d.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nitrendipine (NIT, 10‐20 mg b.i.d.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2540654

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 266

Group type: COMPARATOR
Intervention: Barrier contraception
Number of subjects: 266
Study: 350736

Group type: EXPERIMENTAL
Intervention: MAP (maprotiline)
Number of subjects: 86

Group type: COMPARATOR
Intervention: AMT (amitriptyline)
Number of subjects: 86
Study: 30056216

Group type: EXPERIMENTAL
Intervention: acebilustat 50 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: acebilustat 100 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 200
Study: 27362705

Group type: COMPARATOR
Intervention: Traditional oral medication (Group-I, control)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Abundant water intake (Group-II)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Tympanic ventilation tubes (Group-III)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Sleeping in darkness (Group-IV)
Number of subjects: 297
Study: 25740742

Group type: EXPERIMENTAL
Intervention: Nasointestinal tube (NIT) feeding
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nasogastric tube (NGT) feeding
Number of subjects: 70
Study: 23756915

Group type: COMPARATOR
Intervention: T‐piece resuscitator alone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PediCap CO2 detector
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: NeoStat CO2 detector
Number of subjects: 19
Study: 20966373

Group type: EXPERIMENTAL
Intervention: Culturally sensitive collaborative treatment (CSCT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Care management
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 19132271

Group type: EXPERIMENTAL
Intervention: Predictive equation I: W(kg) = 0.5030 (AC) + 0.5634 (AbC) + 1.3180 (CC) + 0.0339 (SSSF) - 43.1560
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Predictive equation II: W(kg) = 0.4808 (AC) + 0.5646 (AbC) + 1.3160 (CC) - 42.2450
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Predictive equation IV
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Predictive equation V
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Predictive equation III: W(kg) = 0.5759 (AC) + 0.5263 (AbC) + 1.2452 (CC) - 4.8689 (S) - 32.9241
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Predictive equation V: VH(m) = 63.525 - 3.237(S) - 0.06904(A) + 1.293(HS)
Number of subjects: 100
Study: 15845683

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg daily)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg daily) and Erythromycin (1500 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 12960646

Group type: EXPERIMENTAL
Intervention: Inactivated HAV vaccine (Havrix), 720 Elisa units per 0.5 ml dose, administered at months 0 and 6
Number of subjects: 89

Group type: COMPARATOR
Intervention: Healthy controls, 55 participants (mean age: 4.8 ± 2.7 years)
Number of subjects: 89
Study: 10518370

Group type: EXPERIMENTAL
Intervention: Two estimators for expected quality adjusted survival
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sample-based variance estimates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estimation procedures
Number of subjects: 0
Study: 8808515

Group type: EXPERIMENTAL
Intervention: Isokinetic training
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study: 1753043

Group type: EXPERIMENTAL
Intervention: Aerobic exercise condition
Number of subjects: 101

Group type: COMPARATOR
Intervention: Non‐aerobic yoga
Number of subjects: 101

Group type: COMPARATOR
Intervention: Wait list non‐exercise control group
Number of subjects: 101
Study: 6970272

Group type: EXPERIMENTAL
Intervention: Rifampin prophylaxis (20 mg/kg once daily for four days)
Number of subjects: 39
Study: 31884186

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no stimulation)
Number of subjects: 0
Study: 31464176

Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 100

Group type: COMPARATOR
Intervention: Right ventricular (RV) pacing
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined BiV pacing and defibrillation (BiV-D) devices
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Biventricular pacemaker (BiV-P)
Number of subjects: 100
Study: 28406936

Group type: EXPERIMENTAL
Intervention: Exercise before task practice
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Exercise after task practice
Number of subjects: 29

Group type: COMPARATOR
Intervention: Task practice only
Number of subjects: 29
Study: 26505161

Group type: EXPERIMENTAL
Intervention: Virtual environment (LIVE site) with synchronous classes and peer support for self-management.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Traditional asynchronous Web format with the same informational and educational content.
Number of subjects: 300
Study: 23318842

Group type: EXPERIMENTAL
Intervention: Semistructured interview
Number of subjects: 384

Group type: COMPARATOR
Intervention: Usual interview
Number of subjects: 384
Study: 22010250

Group type: EXPERIMENTAL
Intervention: PHL-NP122 (10^6 spores/g of feed)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nitarsone (0.019%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PHL-MM65 (10^6 spores/g of feed)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PHL-NP122 and PHL-MM65
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nitarsone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 10
Study: 19321970

Group type: EXPERIMENTAL
Intervention: Comparator (antidepressant)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 8-week trials
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 12-week trials
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 17446205

Group type: EXPERIMENTAL
Intervention: alpha-lactalbumin (40 g)
Number of subjects: 28

Group type: COMPARATOR
Intervention: casein-derived control protein
Number of subjects: 28
Study: 14736964

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 60
Study: 10795721

Group type: EXPERIMENTAL
Intervention: Cognitive task (math task involving subtraction by threes)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control task (balance only)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cognitive task (math task)
Number of subjects: 26
Study: 9505387

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid sorption
Number of subjects: 16
Study: 8417039

Group type: EXPERIMENTAL
Intervention: Computer-assisted instructional program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Literature-based educational units
Number of subjects: 20
Study: 3092656

Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms twice daily
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms in the morning
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg three times daily and 400 mg at night
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g four times daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 29628759

Group type: EXPERIMENTAL
Intervention: AZD7624
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 27435836

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex) intravenous infusion (0.24 to 0.6 μg/kg/h) for <24 hours postoperatively
Number of subjects: 505
Study: 22716129

Group type: EXPERIMENTAL
Intervention: Four-layer compression bandage system
Number of subjects: 103

Group type: COMPARATOR
Intervention: Class 3 compression hosiery
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 103
Study: 22446609

Group type: EXPERIMENTAL
Intervention: Four cycles of ABVD followed by 30 Gy of involved-field radiation therapy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Two cycles of ABVD followed by 20 Gy of involved-field radiation therapy
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 30 Gy of involved-field radiation therapy
Number of subjects: 98

Group type: COMPARATOR
Intervention: 20 Gy of involved-field radiation therapy
Number of subjects: 98
Study: 20406769

Group type: EXPERIMENTAL
Intervention: Rhythm control strategy
Number of subjects: 1131

Group type: COMPARATOR
Intervention: Rate control strategy
Number of subjects: 1131
Study: 19552060

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects (no antihypertensive therapy)
Number of subjects: 0
Study: 15911668

Group type: EXPERIMENTAL
Intervention: Indirect percutaneous reduction and external fixation (n = 88)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Open reduction and internal fixation (n = 91)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 179
Study: 12883138

Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors (SRIs) including clomipramine, fluvoxamine, fluoxetine, sertraline, and paroxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switching, augmentation, or novel-agent strategies for patients who do not respond to SRIs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic invasive techniques
Number of subjects: 0
Study: 11021272

Group type: EXPERIMENTAL
Intervention: Medical treatment consisting of ACE inhibitors (91% of patients), ACE inhibitor dosage (52% of recommended dose), β‐blockers (42%), diuretics (70%), digitalis (63%)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Implanted defibrillators (1.4% of patients)
Number of subjects: 512
Study: 8750753

Group type: EXPERIMENTAL
Intervention: Frequent telephone contact during the first 3 months post-dispensing
Number of subjects: 55

Group type: COMPARATOR
Intervention: No frequent telephone contact (Control)
Number of subjects: 55
Study: 2336056

Group type: EXPERIMENTAL
Intervention: Solution A (sucrose and maltodextrin)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Solution B (glucose)
Number of subjects: 13
Study: 6986133

Group type: EXPERIMENTAL
Intervention: Diazepam (15 to 25 mg/day)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 31199749

Group type: EXPERIMENTAL
Intervention: Adper Single Bond 2
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Scotchbond Universal
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional aging (6 months of water storage)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Accelerated aging (pH‐cycling method)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Negative control (immediate bond strength)
Number of subjects: 72
Study: 30419850

Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI) grade 1
Number of subjects: 1403

Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI) grade 2
Number of subjects: 1403

Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI) grade ≥3
Number of subjects: 1403

Group type: COMPARATOR
Intervention: Adenocarcinomas
Number of subjects: 1403

Group type: COMPARATOR
Intervention: Squamous cell carcinomas
Number of subjects: 1403

Group type: COMPARATOR
Intervention: Small cell cancers
Number of subjects: 1403
Study: 26848937

Group type: EXPERIMENTAL
Intervention: Mama kits (US$4 incentive)
Number of subjects: 30